# Media overview

Explore our latest news releases and media information.

## News releases

[The hidden impact of veterinary care: new insights from a global survey of veterinarians](/content/ca/hidden-impact-veterinary-care "The hidden impact of veterinary care"/index.html)

June 23, 2026

### The hidden impact of veterinary care: new insights from a global survey of veterinarians

[Read more](/content/ca/hidden-impact-veterinary-care "Read more about \"The hidden impact of veterinary care: new insights from a global survey of veterinarians\""/index.html)

[Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity](/content/ca/press-release-0 "Press release"/index.html)

June 07, 2026

### Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

[Read more](/content/ca/press-release-0 "Read more about \"Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity\""/index.html)

[Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial](/content/ca/press-release "Press release"/index.html)

April 29, 2026

### Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

[Read more](/content/ca/press-release "Read more about \"Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial\""/index.html)

### Media contacts

[Sara McClelland](mailto:sara.mcclelland@boehringer-ingelheim.com)

Sara McClelland  
Communications, Media & Public Relations  
Director, Communications  
Phone (905) 631-4713  
Mobile (905) 599-2364

[Merry Garbutt](mailto:merry.garbutt@boehringer-ingelheim.com)

Merry Garbutt  
Communications, Media & Public Relations  
Corporate Communications  
Phone (905) 631-4531  
Mobile (647) 637-8265

[Anne Coffey](mailto:anne.coffey@boehringer-ingelheim.com)

Anne Coffey  
Specialist, Brand Communications  
Phone (416) 526-5388

[Pilar Iglesias](mailto:pilar.iglesias@boehringer-ingelheim.com)

Pilar Iglesias  
Healthcare Affairs Communications Manager  
Phone: (647) 271-4717

### News material

Access our media pool.

[Read more](/content/ca/new-material "Read more"/index.html)

### References